DK3842442T3 - Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet - Google Patents
Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet Download PDFInfo
- Publication number
- DK3842442T3 DK3842442T3 DK21158664.9T DK21158664T DK3842442T3 DK 3842442 T3 DK3842442 T3 DK 3842442T3 DK 21158664 T DK21158664 T DK 21158664T DK 3842442 T3 DK3842442 T3 DK 3842442T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- methods
- arginase activity
- inhibiting arginase
- inhibiting
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title 1
- 108700024123 Arginases Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438092P | 2016-12-22 | 2016-12-22 | |
| US201662439614P | 2016-12-28 | 2016-12-28 | |
| EP17829574.7A EP3559009B1 (en) | 2016-12-22 | 2017-12-22 | Compositions and methods for inhibiting arginase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3842442T3 true DK3842442T3 (da) | 2024-02-05 |
Family
ID=60972528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17829574.7T DK3559009T3 (da) | 2016-12-22 | 2017-12-22 | Sammensætninger og metoder til inhibition af arginaseaktivitet |
| DK21158664.9T DK3842442T3 (da) | 2016-12-22 | 2017-12-22 | Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17829574.7T DK3559009T3 (da) | 2016-12-22 | 2017-12-22 | Sammensætninger og metoder til inhibition af arginaseaktivitet |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US10287303B2 (da) |
| EP (2) | EP3842442B1 (da) |
| JP (2) | JP7018949B2 (da) |
| KR (1) | KR102579849B1 (da) |
| CN (2) | CN110382508B (da) |
| AU (2) | AU2017382405B2 (da) |
| BR (1) | BR112019012589B1 (da) |
| CA (1) | CA3046987A1 (da) |
| CL (1) | CL2019001711A1 (da) |
| CO (1) | CO2019007839A2 (da) |
| CR (1) | CR20190339A (da) |
| CY (1) | CY1124483T1 (da) |
| DK (2) | DK3559009T3 (da) |
| EC (1) | ECSP19045511A (da) |
| ES (1) | ES2881395T3 (da) |
| HR (1) | HRP20210848T1 (da) |
| HU (1) | HUE054272T2 (da) |
| IL (2) | IL292677A (da) |
| LT (1) | LT3559009T (da) |
| MD (1) | MD3559009T2 (da) |
| MX (2) | MX2019007471A (da) |
| MY (1) | MY197478A (da) |
| NZ (1) | NZ754364A (da) |
| PE (1) | PE20191541A1 (da) |
| PH (1) | PH12019501396A1 (da) |
| PL (1) | PL3559009T3 (da) |
| PT (1) | PT3559009T (da) |
| RS (1) | RS61996B1 (da) |
| SG (2) | SG10201911243WA (da) |
| SI (1) | SI3559009T1 (da) |
| TW (1) | TWI818902B (da) |
| WO (1) | WO2018119440A1 (da) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2632927T3 (da) | 2010-10-26 | 2016-04-11 | Mars Inc | Boronater som arginsaseinhibitorer |
| ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| CA3005727A1 (en) | 2015-11-19 | 2017-05-26 | Incyte Corporation | Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators |
| PE20230731A1 (es) | 2015-12-22 | 2023-05-03 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| PE20190731A1 (es) | 2016-06-20 | 2019-05-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
| ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| BR112019012957A2 (pt) * | 2016-12-22 | 2019-11-26 | Incyte Corp | derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1 |
| KR102579849B1 (ko) * | 2016-12-22 | 2023-09-18 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기나제 활성을 억제시키기 위한 조성물 및 방법 |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| MY197635A (en) | 2016-12-22 | 2023-06-29 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| CN108322295B (zh) | 2017-01-17 | 2021-12-24 | 维沃移动通信有限公司 | 一种边带信息的发送方法、接收方法、发送端和接收端 |
| SG11202007739XA (en) | 2018-02-17 | 2020-09-29 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| US10851099B2 (en) | 2018-03-29 | 2020-12-01 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
| CN112752756A (zh) | 2018-05-11 | 2021-05-04 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| MX2021002042A (es) | 2018-08-22 | 2021-04-28 | Astrazeneca Ab | Inhibidores de arginasa y sus metodos de uso. |
| WO2020131598A1 (en) * | 2018-12-18 | 2020-06-25 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| EA202192114A1 (ru) * | 2019-02-08 | 2021-12-01 | Астразенека Аб | Ингибиторы аргиназы и способы их применения |
| US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
| CN110759843A (zh) * | 2019-09-30 | 2020-02-07 | 东北师范大学 | 一种氟叠氮取代的四元杂环化合物的制备和应用 |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| PE20230407A1 (es) | 2019-11-11 | 2023-03-07 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| CA3188639A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| WO2022016195A1 (en) | 2020-07-17 | 2022-01-20 | Incyte Corporation | Processes for the preparation of arginase inhibitors and their synthetic intermediates |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| CN112387262B (zh) * | 2020-11-10 | 2021-12-07 | 泰州学院 | 一种基于光催化交联蛋白的手性固定相的制备方法、手性固定相及应用 |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| WO2023133505A2 (en) * | 2022-01-07 | 2023-07-13 | The Trustees Of Columbia University In The City Of New York | Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia |
| US20230295124A1 (en) | 2022-03-17 | 2023-09-21 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2024086273A1 (en) | 2022-10-21 | 2024-04-25 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| CN1229110C (zh) | 1997-07-29 | 2005-11-30 | 阿尔康实验室公司 | 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物 |
| CA2305703A1 (en) | 1997-10-10 | 1999-04-22 | David W. Christianson | Compositions and methods for inhibiting arginase activity |
| WO1999038504A1 (en) | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| WO2002004465A1 (en) | 2000-07-06 | 2002-01-17 | Fal Diagnostics | Methods and kits for the detection of arginine compounds |
| CA2431080A1 (en) | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| ATE444732T1 (de) | 2003-08-07 | 2009-10-15 | Allergan Inc | Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| US20090298912A1 (en) | 2005-07-01 | 2009-12-03 | The Johns Hopkins University | Arginase II: A Target treatment of aging heart and heart failure |
| US20070203140A1 (en) | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| US20080146624A1 (en) | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| US20080119491A1 (en) | 2006-09-19 | 2008-05-22 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008058178A1 (en) | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| PL2099447T3 (pl) | 2006-11-22 | 2013-06-28 | Incyte Holdings Corp | Imidazotriazyny i imidazopirmidyny jako inhibitory kinaz |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| US8748469B2 (en) | 2008-04-24 | 2014-06-10 | Newlink Genetics Corporation | IDO inhibitors |
| PE20110308A1 (es) | 2008-07-08 | 2011-06-10 | Incyte Corp | 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa |
| EP2389352B1 (en) | 2009-01-26 | 2019-05-08 | The Trustees Of The University Of Pennsylvania | Arginase inhibitors and methods of use |
| WO2011082245A2 (en) | 2009-12-31 | 2011-07-07 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| EP2547366A4 (en) | 2010-03-18 | 2013-08-07 | Univ Colorado State Res Found | INHIBITING AGENTS OF SUPPRESSIVE MYELOID CELLS |
| NZ603364A (en) | 2010-04-22 | 2015-06-26 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
| CA2837400C (en) | 2010-04-24 | 2017-12-12 | Viamet Pharmaceuticals, Inc. | 5-(optionally substituted phenyl) pyridin-2-yl compounds as metalloenzyme inhibitors |
| RS60310B1 (sr) * | 2010-08-10 | 2020-07-31 | Rempex Pharmaceuticals Inc | Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe |
| US9023851B2 (en) | 2010-08-27 | 2015-05-05 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| DK2632927T3 (da) * | 2010-10-26 | 2016-04-11 | Mars Inc | Boronater som arginsaseinhibitorer |
| EP2632903A4 (en) | 2010-10-28 | 2014-11-26 | Viamet Pharmaceuticals Inc | METALLOENZYMHEMMERVERBINDUNGEN |
| JP5828343B2 (ja) | 2010-11-13 | 2015-12-02 | イノクリン ファーマシューティカルズ，インコーポレイテッド | 金属酵素阻害化合物 |
| CN103328452A (zh) | 2010-12-13 | 2013-09-25 | 威尔金制药有限公司 | 金属酶抑制剂化合物 |
| WO2012091757A1 (en) * | 2010-12-31 | 2012-07-05 | Corridor Pharmaceuticals, Inc. | Arginase inhibitors and methods of use thereof |
| NO2694640T3 (da) | 2011-04-15 | 2018-03-17 | ||
| CN105884743B (zh) | 2011-06-19 | 2019-08-06 | 威尔金制药(Nc)有限公司 | 金属酶抑制剂化合物 |
| EA024385B1 (ru) | 2011-06-19 | 2016-09-30 | Ваймет Фармасьютикалс, Инк. | Соединения, ингибирующие металлоферменты |
| KR101964195B1 (ko) | 2011-06-23 | 2019-04-01 | 비아멧 파마슈티컬즈(엔씨), 인코포레이티드 | 금속효소 억제제 화합물 |
| JP2014525442A (ja) | 2011-08-30 | 2014-09-29 | ヴィアメット ファーマスーティカルズ，インコーポレイテッド | 金属酵素阻害化合物 |
| WO2013059437A1 (en) | 2011-10-19 | 2013-04-25 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| US9957271B2 (en) * | 2011-10-20 | 2018-05-01 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| PT2788343T (pt) | 2011-12-11 | 2018-06-01 | Viamet Pharmaceuticals Nc Inc | Compostos inibidores de metaloenzimas |
| IN2014DN06792A (da) | 2012-01-20 | 2015-05-22 | Viamet Pharmaceuticals Inc | |
| KR20140117636A (ko) | 2012-01-28 | 2014-10-07 | 메르크 파텐트 게엠베하 | 트리아졸로[4,5-ｄ]피리미딘 유도체 |
| CN104114557B (zh) | 2012-02-21 | 2017-10-24 | 默克专利股份公司 | 作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪 |
| EP2817306B1 (en) | 2012-02-21 | 2015-09-16 | Merck Patent GmbH | Cyclic diaminopyrimidine derivatives as syk inhibitors |
| WO2013131609A1 (en) | 2012-03-07 | 2013-09-12 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| BR112014026057B1 (pt) | 2012-04-18 | 2020-10-13 | Mars, Incorporated | composto inibidor da arginase, composição farmacêutica e uso do composto |
| ES2618004T3 (es) | 2012-08-07 | 2017-06-20 | Merck Patent Gmbh | Derivados de piridopirimidina como inhibidores de proteínas quinasas |
| US20150246898A1 (en) | 2012-09-12 | 2015-09-03 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds |
| CA2898615A1 (en) | 2013-01-28 | 2014-07-31 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| AU2014224976B2 (en) | 2013-03-05 | 2017-09-28 | Merck Patent Gmbh | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| EP2964649B1 (en) | 2013-03-05 | 2017-05-10 | Merck Patent GmbH | Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer |
| AU2014265957A1 (en) | 2013-03-14 | 2015-09-10 | Curadev Pharma Private Ltd. | Inhibitors of the kynurenine pathway |
| WO2014141110A2 (en) | 2013-03-14 | 2014-09-18 | Curadev Pharma Pvt. Ltd. | Aminonitriles as kynurenine pathway inhibitors |
| RU2667509C2 (ru) | 2013-03-14 | 2018-09-21 | Ньюлинк Джинетикс Корпорейшин | Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана |
| EA028424B1 (ru) | 2013-03-15 | 2017-11-30 | Бристол-Майерс Сквибб Компани | Ингибиторы ido |
| JP6313416B2 (ja) | 2013-03-15 | 2018-04-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｉｄｏ阻害剤 |
| WO2014180524A1 (en) | 2013-05-06 | 2014-11-13 | Merck Patent Gmbh | Macrocycles as kinase inhibitors |
| US9447073B2 (en) | 2013-05-28 | 2016-09-20 | Viamet Pharmaceuticals, Inc. | Fungicidal compositions |
| MX2015017486A (es) | 2013-07-01 | 2016-03-21 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (dio). |
| EA201690152A1 (ru) | 2013-07-11 | 2016-05-31 | Бристол-Майерс Сквибб Компани | Ингибиторы ido |
| WO2015017402A1 (en) | 2013-07-29 | 2015-02-05 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of biofilm infections |
| MX2016002075A (es) | 2013-08-27 | 2016-05-26 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (ido). |
| CA2927794A1 (en) | 2013-10-25 | 2015-04-30 | Pharmacyclics Llc | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
| EP3066085B1 (en) | 2013-11-08 | 2020-05-13 | Incyte Holdings Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
| NZ722891A (en) | 2014-02-04 | 2021-07-30 | Incyte Corp | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| US9944664B2 (en) | 2014-04-15 | 2018-04-17 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds as fungicides |
| CA2945671A1 (en) | 2014-04-15 | 2015-10-22 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds as fungicides |
| WO2015188085A1 (en) | 2014-06-06 | 2015-12-10 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| TW201619133A (zh) | 2014-08-21 | 2016-06-01 | 裘拉德製藥私人有限公司 | 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物 |
| EP3189054B1 (en) | 2014-09-05 | 2019-07-24 | Merck Patent GmbH | (1-fluoro-cyclohex-1-yl)-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer |
| CN105879030A (zh) | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| GB201417369D0 (en) | 2014-10-01 | 2014-11-12 | Redx Pharma Ltd | Compounds |
| WO2016057986A1 (en) | 2014-10-10 | 2016-04-14 | The Trustees Of Columbia University In The City Of New York | Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof |
| GB201418300D0 (en) | 2014-10-15 | 2014-11-26 | Redx Pharma Ltd | Compounds |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| CA2964276A1 (en) | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| US20180078515A1 (en) | 2015-03-20 | 2018-03-22 | Sammy Oyoo OPIYO | Use of suramin and arginase inhibitors in malignant neoplasia |
| MX2017012699A (es) | 2015-04-03 | 2018-02-09 | Incyte Corp | Compuestos heterociclicos como inhibidores de demetilasa 1 especifica de lisina (lsd1). |
| JP2018516238A (ja) | 2015-04-03 | 2018-06-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
| TW201705955A (zh) | 2015-05-14 | 2017-02-16 | 輝瑞大藥廠 | 包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑及抗－ｐｄ１／抗－ｐｄ－ｌ１抗體之組合療法 |
| WO2016196890A1 (en) | 2015-06-04 | 2016-12-08 | Vtv Therapeutics Llc | Inhibitors of hexokinase and methods of use thereof |
| JP2018520352A (ja) | 2015-06-23 | 2018-07-26 | カリセラ バイオサイエンシズ，インコーポレイテッド | アルギナーゼ活性を阻害するための組成物および方法 |
| CN108271371B (zh) * | 2015-10-30 | 2021-02-09 | 卡里塞拉生物科学股份公司 | 用于抑制精氨酸酶活性的组合物和方法 |
| KR102579849B1 (ko) * | 2016-12-22 | 2023-09-18 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기나제 활성을 억제시키기 위한 조성물 및 방법 |
-
2017
- 2017-12-22 KR KR1020197021468A patent/KR102579849B1/ko active IP Right Grant
- 2017-12-22 PT PT178295747T patent/PT3559009T/pt unknown
- 2017-12-22 RS RS20210763A patent/RS61996B1/sr unknown
- 2017-12-22 LT LTEP17829574.7T patent/LT3559009T/lt unknown
- 2017-12-22 BR BR112019012589-2A patent/BR112019012589B1/pt active IP Right Grant
- 2017-12-22 MY MYPI2019003368A patent/MY197478A/en unknown
- 2017-12-22 CA CA3046987A patent/CA3046987A1/en active Pending
- 2017-12-22 CN CN201780080358.1A patent/CN110382508B/zh active Active
- 2017-12-22 EP EP21158664.9A patent/EP3842442B1/en active Active
- 2017-12-22 NZ NZ754364A patent/NZ754364A/en unknown
- 2017-12-22 DK DK17829574.7T patent/DK3559009T3/da active
- 2017-12-22 TW TW106145440A patent/TWI818902B/zh active
- 2017-12-22 PE PE2019001311A patent/PE20191541A1/es unknown
- 2017-12-22 PL PL17829574T patent/PL3559009T3/pl unknown
- 2017-12-22 MX MX2019007471A patent/MX2019007471A/es unknown
- 2017-12-22 SG SG10201911243WA patent/SG10201911243WA/en unknown
- 2017-12-22 MD MDE20191232T patent/MD3559009T2/ro unknown
- 2017-12-22 US US15/853,310 patent/US10287303B2/en active Active
- 2017-12-22 AU AU2017382405A patent/AU2017382405B2/en active Active
- 2017-12-22 EP EP17829574.7A patent/EP3559009B1/en active Active
- 2017-12-22 IL IL292677A patent/IL292677A/en unknown
- 2017-12-22 JP JP2019534159A patent/JP7018949B2/ja active Active
- 2017-12-22 ES ES17829574T patent/ES2881395T3/es active Active
- 2017-12-22 HU HUE17829574A patent/HUE054272T2/hu unknown
- 2017-12-22 CN CN202210836886.8A patent/CN114989205A/zh active Pending
- 2017-12-22 CR CR20190339A patent/CR20190339A/es unknown
- 2017-12-22 DK DK21158664.9T patent/DK3842442T3/da active
- 2017-12-22 SI SI201730835T patent/SI3559009T1/sl unknown
- 2017-12-22 SG SG10201911240PA patent/SG10201911240PA/en unknown
- 2017-12-22 WO PCT/US2017/068307 patent/WO2018119440A1/en active Application Filing
-
2019
- 2019-03-29 US US16/370,857 patent/US10597411B2/en not_active Expired - Fee Related
- 2019-06-18 PH PH12019501396A patent/PH12019501396A1/en unknown
- 2019-06-19 CL CL2019001711A patent/CL2019001711A1/es unknown
- 2019-06-20 IL IL267532A patent/IL267532B/en unknown
- 2019-06-20 MX MX2020013649A patent/MX2020013649A/es unknown
- 2019-06-26 EC ECSENADI201945511A patent/ECSP19045511A/es unknown
- 2019-07-22 CO CONC2019/0007839A patent/CO2019007839A2/es unknown
-
2020
- 2020-02-14 US US16/792,186 patent/US11021495B2/en active Active
-
2021
- 2021-01-20 US US17/153,804 patent/US20210261573A1/en active Pending
- 2021-05-27 HR HRP20210848TT patent/HRP20210848T1/hr unknown
- 2021-07-05 CY CY20211100602T patent/CY1124483T1/el unknown
-
2022
- 2022-02-01 JP JP2022014021A patent/JP2022066199A/ja not_active Abandoned
- 2022-02-17 AU AU2022201072A patent/AU2022201072A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3842442T3 (da) | Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet | |
| DK3368541T3 (da) | Sammensætninger og metoder til inhibiering af arginaseaktivitet | |
| DK3510157T3 (da) | Pd-1-homing-endonucleasevarianter, sammensætninger og fremgangsmåder til anvendelse | |
| DK3386534T3 (da) | Sammensætninger og fremgangsmåder til internalisering af enzymer | |
| DK3325669T3 (da) | Sammensætninger og fremgangsmåder til RNA-analyse | |
| DK3888658T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
| DK3390631T3 (da) | Fremgangsmåder og sammensætninger til t-rna-baseret guide-rna-ekspression | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| DK3402483T3 (da) | Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler | |
| DK3092256T3 (da) | Forbindelser og sammensætninger til immunterapi | |
| DK3134130T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3137605T3 (da) | Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression | |
| DK3108009T3 (da) | Fremgangsmåder og sammensætninger til DNA-profilering | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3319948T3 (da) | Acesulfam-kaliumsammensætninger og fremgangsmåder til fremstilling af disse | |
| DK3322695T3 (da) | Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse | |
| DK3353168T3 (da) | Forbindelser og fremgangsmåder til at inhibere jak | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK2924093T3 (da) | Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse | |
| DK3394272T3 (da) | Sammensætninger og fremgangsmåder til effektiv målretning af transgener | |
| DK3394259T3 (da) | Sammensætninger og fremgangsmåder til reducering af tau-ekspression |